Eli Lilly Crushes Views As Zepbound, Mourjaro Sales Boom - Investor's Business Daily
- Eli Lilly Crushes Views As Zepbound, Mourjaro Sales Boom Investor's Business Daily
- Excitement grows around Eli Lilly's GLP-1 drugs in Q2 earnings Yahoo Finance
- Eli Lilly’s stock leaps after big earnings beat, boosted by strength in Mounjaro and Zepbound sales MarketWatch
- Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar CNBC